Inmune Bio, Inc. Commitments Disclosure
NOTE 12 – COMMITMENTS AND CONTINGENCIES
Litigation
The Company is subject to claims and suits that arise from time to time in the ordinary course of our business. Although management currently believes that resolving claims against the Company, individually or in aggregate, will not have a material adverse impact in the Company’s consolidated financial statements, these matters are subject to inherent uncertainties and management’s view of these matters may change in the future.
Commitments
During April 2025, the Company’s wholly-owned subsidiary, INmune Bio International Ltd., entered into a 2-year collaboration agreement with a vendor whereby it makes payments to the vendor in exchange for services pursuant to manufacturing CORDStrom in the United Kingdom. which the Company records within research and development expenses. During the year ended December 31, 2025, the Company recorded approximately $869,000 in research and development expense pursuant to the collaboration agreement. A summary of the commitments payable for these services pursuant to the agreement is as follows as of December 31, 2025:
| (in thousands, except years) | ||||
| 2026 | $ | 1,432 | ||
| 2027 | 1,216 | |||
| Total | $ | 2,648 | ||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 30, 2026 | Showing above |
| 2023 | Mar 28, 2024 | |
| 2022 | Mar 2, 2023 | |
| 2021 | Mar 3, 2022 | |
| 2018 | Mar 29, 2019 | |
About Commitments Disclosures
Commitments and contingencies disclosures catalog a company's off-balance-sheet obligations and legal exposures — purchase commitments, guarantee arrangements, pending litigation, and regulatory proceedings. These items represent potential future cash outflows that may not appear as liabilities on the balance sheet until they become probable and estimable.
Key signals: litigation reserves and disclosed loss ranges quantify management's estimate of legal exposure, but unquantified "reasonably possible" losses often represent the larger risk. Watch for changes in language around pending cases — shifts from "remote" to "reasonably possible" or increases in estimated loss ranges signal deteriorating outcomes. Unconditional purchase obligations and take-or-pay contracts create fixed cost structures that reduce operational flexibility. Guarantee arrangements for subsidiaries or joint ventures can create cascading obligations. Compare the total commitment schedule against projected free cash flow to assess whether the company can meet its obligations without additional financing.